Cidara Therapeutics, which is developing novel therapies for fungal infections, announced terms for its IPO on Monday.
The San Diego, CA-based company plans to raise $60 million by offering 4.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Cidara Therapeutics would command a market value of $190 million.
Cidara Therapeutics, which was founded in 2012, plans to list on the NASDAQ under the symbol CDTX. Jefferies and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of April 13, 2015.
